Deals
AstraZeneca CEO Faces Shareholder Backlash on Pay
- Investment Association applies “red top” to drugmaker’s policy
- Company faced shareholder revolts on pay in 2018, 2017
This article is for subscribers only.
AstraZeneca Plc could face a shareholder revolt over its chief executive officer’s pay package this month after the U.K. Investment Association recommended investors vote against it, according to a person with knowledge of the situation.
The trade body for U.K. investment managers has applied a so-called red top alert to AstraZeneca’s pay policy because of its pension contributions, said the person, who didn’t want to be identified because the classification isn’t public.